Indian drugmaker Granules to tighten oversight after US FDA warning, exec says

Amid growing scrutiny from the U.S. FDA over documentation practices and contamination issues, Granules India is reinforcing its manufacturing framework. The company is turning to advanced digitization and automating record management to bolster data accuracy and compliance. By instituting these reforms, Granules India is proactively tackling regulatory challenges while ensuring excellence in product quality across all facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xRD2gdE
via IFTTT